Private Advisor Group LLC Has $3.03 Million Stock Holdings in Humacyte, Inc. (NASDAQ:HUMA)

Private Advisor Group LLC increased its position in Humacyte, Inc. (NASDAQ:HUMA) by 60.7% in the fourth quarter, Holdings Channel.com reports. The firm owned 599,700 shares of the company’s stock after acquiring an additional 226,590 shares during the period. Private Advisor Group LLC’s holdings in Humacyte were worth $3,028,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in HUMA. Vontobel Holding Ltd. acquired a new position in Humacyte during the fourth quarter valued at approximately $50,000. Brookstone Capital Management bought a new position in shares of Humacyte during the fourth quarter worth $56,000. ACT Wealth Management LLC acquired a new position in shares of Humacyte in the 4th quarter valued at $57,000. Concurrent Investment Advisors LLC acquired a new position in shares of Humacyte in the 3rd quarter valued at $75,000. Finally, FORA Capital LLC bought a new stake in shares of Humacyte in the 3rd quarter valued at $96,000. 44.71% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on HUMA shares. HC Wainwright reiterated a “buy” rating and set a $15.00 target price (up from $12.00) on shares of Humacyte in a report on Friday, December 20th. D. Boral Capital reaffirmed a “buy” rating and issued a $25.00 price target on shares of Humacyte in a research note on Tuesday, January 21st. Finally, Benchmark boosted their price objective on shares of Humacyte from $15.00 to $17.00 and gave the company a “buy” rating in a research report on Monday, December 23rd. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $13.71.

Humacyte Stock Down 9.0 %

Shares of HUMA stock opened at $3.22 on Tuesday. Humacyte, Inc. has a 12 month low of $2.81 and a 12 month high of $9.97. The company’s fifty day simple moving average is $4.42 and its 200-day simple moving average is $5.07. The firm has a market cap of $405.27 million, a PE ratio of -2.40 and a beta of 1.30.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.